Enfortumab vedotin plus pembrolizumab improved EFS, OS, and pCR rates in MIBC patients ineligible for cisplatin-based chemotherapy. The combination therapy showed a median EFS and OS that were not ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback